Who makes Placebo for Tifcemalimab?

Placebo for Tifcemalimab is developed by Shanghai Junshi Bioscience Co., Ltd..

What development phase is Placebo for Tifcemalimab in?

Placebo for Tifcemalimab is in Phase 3.

Last reviewed 2026-04-23 · How we verify

Placebo for Tifcemalimab

Shanghai Junshi Bioscience Co., Ltd. · Phase 3 active Small molecule

A placebo control arm that provides no active therapeutic effect, used as a comparator in clinical trials of Tifcemalimab.

At a glance

Generic name	Placebo for Tifcemalimab
Sponsor	Shanghai Junshi Bioscience Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Placebos are inert substances administered in controlled trials to establish baseline disease progression and distinguish true drug efficacy from placebo response. In this Phase 3 trial, the placebo arm serves as the control group against which Tifcemalimab's therapeutic benefits are measured.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo for Tifcemalimab CI brief — competitive landscape report
Placebo for Tifcemalimab updates RSS · CI watch RSS
Shanghai Junshi Bioscience Co., Ltd. portfolio CI